Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AssigneeMerck Frosst Canada, Inc.
InventorsJacques Y. Gauthier, Cheuk K. Lau, Yves LeBlanc, Chun-Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
Life of this patent
Estimating the term…
Abstract
The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Claims21
A compound of Formula I ##STR46## or a pharmaceutically acceptable salt thereof wherein:
- --A--B--D-- is selected from the group consisting of:
- (a) --CH.dbd.CH--CH.dbd.,
- (b) --CH.dbd.CH--C(OH).dbd.,
- (c) --C(OH).dbd.CH--C.dbd.,
- (d) --N.dbd.CH--CH.dbd.,
- (e) --N.dbd.N--CH.dbd.,
- (f) --N.dbd.N--NH--,
- (g) --N.dbd.N--N.dbd.,
- (h) --N.dbd.CH--NH--,
- (i) --N.dbd.CH--N.dbd.,
- (j) --CH.dbd.N--NH--,
- (k) --CH.dbd.N--N.dbd.,
- (l) --CH.dbd.N--CH.dbd.,
- (m) --CH.dbd.CH--NH--,
- (n) --CH.dbd.CH--N.dbd.,
- (o) --S--CH.dbd.CH--,
- (p) --O--CH.dbd.CH--,
- (q) --CH.dbd.CH--O--,
- (r) --CH.dbd.CH--S--,
- (s) --CH.dbd.N--S--,
- (t) --CH=N--O--,
- (u) --N--CH--S--,
- (v) --N=CH--O--,
- (w) --S--CH=N--,
- (x) --O--CH=N--,
- (y) --N=N--S--,
- (z) --N=N--O--,
- (aa) --S--N=N--,
- (bb) --O--N=N--and
- (cc) --C(OH)=CH--S--;
- wherein definitions (a) through (cc) of --A--B--D-- is mono- or di-substituted, the substituents being independently selected from the group consisting of:
- (1) hydrogen.
- (2) CF.sub.3,
- (3) CN,
- (4) halo, including F, Cl, Br, I,
- (5) C.sub.1-6 alkyl,
- X is N, NR.sup.4 O, or S;
- R.sup.1 is selected from the group consisting of:
- (a) S(O).sub.2 CH.sub.3,
- (b) S(O).sub.2 NH.sub.2,
- (c) S(O).sub.2 NHCOCF.sub.3,
- (d) S(O)(NH)CH.sub.3,
- (e) S(O)(NH)NH.sub.2,
- (f) S(O)(NH)N HCOCF.sub.3,
- (g) P(O)(CH.sub.3)OH, and
- (h) P(O)(CH.sub.3)NH.sub.2,
- R.sup.2 and R.sup.3 are each independently selected from the group consisting of:
- (a) hydrogen,
- (b) halo,
- (c) C.sub.1-6 alkoxy,
- (d) C.sub.1-6 alkylthio,
- (c) CN,
- (f) C.sub.1-3 fluoroalkyl,
- (g) C.sub.1-6 alkyl,
- (h) N.sub.3,
- (i) --CO.sub.2 H,
- (j) --CO.sub.2 --C.sub.1-4 alkyl,
- (k) --C(R.sup.5)(R.sup.6)--OH,
- (l) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl, and
- (m) --C.sub.1-6 alkyl--CO.sub.2 --R.sup.7 ;
- R.sup.4 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, phenyl and benzyl;
- R.sup.5, R.sup.6 and R.sup.7 are each independently selected from the group consisting of:
- (a) hydrogen, and
- (b) C.sub.1-6 alkyl.
The compound of claim 15 wherein --A--B--D-- is selected from the group consisting of:
- (a) --CH.dbd.CH--CH.dbd.,
- (b) --N.dbd.CH--CH.dbd.,
- (c) --N.dbd.N--CH.dbd.,
- (d) --N.dbd.N--NH--,
- (e) --N.dbd.N--N.dbd.,
- (f) --N.dbd.CH--NH--,
- (g) --N.dbd.CH--N.dbd.,
- (h) --CH.dbd.N--NH--,
- (i) --CH.dbd.N--N.dbd.,
- (j) --CH.dbd.CH--N.dbd.,
- (k) --CH.dbd.CH--O--,
- (l) --CH.dbd.CH--S--,
- (m) --CH.dbd.N--S--,
- (n) --N.dbd.CH--S--,
- (o) --S--CH.dbd.N--and
- (p) --N.dbd.N--S--;
- wherein definitions (a) through (p) of --A--B--D-- is mono- or di-substituted, the substituents being independently selected from the group consisting of:
- (1) hydrogen,
- (2) CF.sub.3,
- (3) CN,
- (4) F, Cl, Br and I,
- (5) C.sub.1-4 alkyl,
- X is N, NR.sup.4 or O;
- R.sup.1 is selected from the group consisting of:
- (a) S(O).sub.2 CH.sub.3,
- (b) S(O).sub.2 NH.sub.2,
- (c) S(O)(N H)CH.sub.3,
- (d) S(O)(N H)NH.sub.2,
- R.sup.2 and R.sup.3 are each independently selected from the group consisting of:
- (a) hydrogen,
- (b) halo,
- (c) C.sub.1-4 alkoxy,
- (d) C.sub.1-4 alkylthio,
- (e) CN,
- (f) C.sub.1-3 fluoroalkyl ,
- (g) C.sub.1-4 alkyl,
- (h) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl, and
- R.sup.4 is selected from the group consisting of hydrogen, C.sub.1-4 alkyl, phenyl and benzyl;
- R.sup.5, R.sup.6 and R.sup.7 are each independently selected from the group consisting of:
- (a) hydrogen, and
- (b) C.sub.1-4 alkyl.
A compound selected from
- (a) 5-(4-(Methylsulfonyl)phenyl)-6-phenylimidazo [2,1-b]thiazole and
- (b) 5-phenyl-6-(4-(methylsulfonyl)phenyl)thiazolo[3,2-b]1,3,4-triazole.
Dependencies are inferred from the claim text.